Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Mol Cancer Res. 2016 Jun 3;14(9):869–882. doi: 10.1158/1541-7786.MCR-16-0007

Figure 7. FAK kinase inhibition significantly enhances ATC metastasic burden in vivo using a pretreatment approach.

Figure 7

Mice were injected with 8505C cells and either (A) pretreated with PF-562,271 (50mg/kg, 7d/w) 2 days prior to injection or (B) treated 8 days after injection (post-treat). Bioluminescence detection monitored metastatic progression over time (Pre-treatment: day 7, p≤0.01; day 14, p≤0.05; day 21, p≤0.05; day 35, p≤0.001; t-test. Post-treatment: day 35, p≤0.01; t-test). Results shown are mean bioluminescence signal (photons/second) per group ± SEM at the indicated time points. (Final total metastatic burden of vehicle group = 1.83×109 ± 1.04×109 p/s; PF-271 pretreatment = 4.21×109 ± 2.16×109; PF-271 post-treatment = 4.98×108 ± 1.73×108 p/s). (C) Representative bioluminescence images show 1 minute after injection to demonstrate dissemination through the body. Ventral and dorsal images are shown for representative mice at day 35.